LENZ Therapeutics and Lotus Pharmaceutical have entered into an exclusive agreement for the commercialization of LNZ100 in South Korea and Southeast Asia, which includes potential payments of up to $125 million and double-digit royalties on future sales.

Information on the Target

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical firm focused on pioneering advancements in ophthalmic treatments. The company's flagship product, LNZ100, is the first and only aceclidine-based eye drop aimed at improving near vision for individuals suffering from presbyopia. This condition affects a significant portion of the aging population and presents a substantial market opportunity for innovative therapies. LENZ's commitment lies in enhancing the quality of life for those impacted by this vision impairment.

Headquartered in San Diego, California, LENZ Therapeutics is strategically positioned in the biopharmaceutical landscape. The company has demonstrated its capability in developing effective solutions to address unmet medical needs, and has recently received positive recognition as the FDA accepted the New Drug Application (NDA) for LNZ100 in October 2024.

Industry Overview in South Korea and Southeast Asia

The biopharmaceutical industry in South Korea and Southeast Asia is witnessing rapid growth fueled by the increasing prevalence of medical conditions necessitating innovative treatments. Countries in this region are investing significantly in healthc